Renée Aguiar Lucander

All filings by Renée Aguiar Lucander on record concern Hansa Biopharma AB, in the capacity of chief executive. Between 27 July 2025 and 25 September 2026, the trades on record add up to 3 filings.

Purchases make up the whole of the open-market record (3 purchases, €1.9M). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2026, the count stands at 1 purchase and no sales.

In size, the median ticket on the buying side is €132k. Measured against the company's value, the median purchase equals 0.047% of market capitalisation, across 3 purchases where it is known. None of the 3 purchases we analysed coincided with buying by another insider of the same company within 30 days.

Most recently, on 28 September 2026, the filings show an open-market purchase worth €132k in Hansa Biopharma AB. Filings reach the Finansinspektionen feed a median of 2 days after the trade. For comparison, MAR article 19 gives managers three business days to notify a trade. This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.